SERES Medical Brings MVision’s Cutting Edge and Guideline-Based AI Segmentation Solution to the Turkish Market

Helsinki – September 6, 2021 – MVision AI, the software service provider for radiotherapy treatment planning, announces a new distribution partnership with SERES Medical, the leading Turkish medical equipment provider. 

The agreement entitled SERES Medical the rights to distribute products and services of MVision AI in Turkey. Both SERES Medical and MVision AI will support the commitment to help oncology departments to receive the highest quality, guideline-based, deep learning radiotherapy solution throughout Turkey. MVision AI’s team will be working closely with SERES Medical to guarantee the distribution of timely, consistent, and GDPR compliant radiotherapy services. 

“We are pleased to announce our partnership with MVision. We believe the AI segmentation solution will become a golden standard in radiotherapy daily routines. The power of this tool will bring standardization and consistency for organ-at-risk contouring while hours of manual work will convert into an automated process that will only take minutes.” said Tolga Sengezer, partner at SERES Medical.

“With this partnership, MVision is accelerating growth to  international markets and ushering in a new era of standardization of contouring all over the world. We welcome SERES to join our mission to provide fast, reliable and high-quality AI segmentation solutions for cancer patients undergoing radiotherapy,” said Mahmudul Hasan, CEO and co-founder of MVision AI.  ‘

For further information on SERES Medical:

SERES Medical Logo MVision AI

Seres Medical Consultancy

Website: http://www.seresmed.com.tr 

Tel: +90 312 219 63 11

LinkedIn: https://www.linkedin.com/company/seres-medical-consultancy/

 

To learn more about MVision AI: 

c/o Terkko Health Hub, Haartmaninkatu 4, 00290 Helsinki, Finland.

Tel: +358 (0) 40 5489 229

Website: https://www.mvision.ai 

Email: info@ mvision.ai 

LinkedIn: https://fi.linkedin.com/company/mvisionai 

 

For media inquiries:

Tel: +358 40 500 7915

Email: pr@mvision.ai

Our Newsletter

Subscribe to get information, latest news and other interesting offers about MVision AI

Related Posts

2.2.2024

World Cancer Day – Joining efforts for a better cancer care

World cancer day, celebrated on the 4th of February, was established more than 20 years ago. It represents an initiative of the Union for International Cancer Control (UICC) , the oldest and largest global membership organization dedicated to taking action on cancer. UICC has over 1150 member organizations in 172…

News

30.1.2024

How can AI-based auto-contouring improve the life of patients who need palliative radiation therapy?

Cancer is one of the leading causes of morbidity and death, worldwide. Approximately 18 million people are diagnosed with cancer each year and the number is expected to increase. Pain is experienced by two thirds of patients having advanced, metastatic or terminal disease (1). Other symptoms caused by compression on…

Articles

22.1.2024

MVision AI Announces Partnership with Medron Medical Systems (Canada)

HELSINKI, Finland - January 22, 2024 MVision AI, a premier software service provider of GBS™ (Guideline-Based Segmentation) solution for same-day radiotherapy treatment planning, proudly announces a new distribution partnership with Medron Medical Systems, a leading health equipment provider in Canada. This collaboration follows the receipt of Medical Device License (MDL)…

Press Releases